Expert Interviews

FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.

The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.

Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe

The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.

In this Contemporary Pediatrics® interview, Jamie Alan, RPh, PharmD, PhD, associate professor, Department of Pharmacology and Toxicology, Michigan State University, talks about the potential impacts red dye No. 3 has on children, and why an assembly bill in California is trying to eliminate it.